Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study

Sponsor
University Hospital, Strasbourg, France
Study ID
NCT07560995
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Internuclear ophthalmoplegia is a symptom frequently associated with multiple sclerosis (MS), although other etiologies are possible. Some patients do not meet the diagnostic criteria for MS at the time of the internuclear ophthalmoplegia episode but subsequently convert to MS. Studying this specific clinical situation may help enable earlier diagnosis of MS. The objective is to analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis and to identify factors associated with this conversion. The study hypothesis is that the presence of internuclear ophthalmoplegia is highly suggestive of multiple sclerosis, particularly when cerebrospinal fluid-specific oligoclonal bands are present.

Key Dates

First listed
May 1, 2026
Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
May 31, 2026
Completion
May 31, 2027

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Internuclear ophthalmoplegia
    This is a retrospective cohort study involving patients who have experienced internuclear ophthalmoplegia. For each patient, it is determined whether a diagnosis of multiple sclerosis was established or not.

Primary Outcome Measure

Analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis. [ Time Frame: 1 year ]

Central Contacts

Find similar trials

Nationwide
Multiple sclerosis trialsNeurology trialsBrain disorders trialsAutoimmune disease trials

Related Studies